Role of P53 and MDM2 in treatment response of human germ cell tumors

Journal of Clinical Oncology

Volumn 20, Issue 6, 2002, Pages 1551-1561

  Kersemaekers, Anne Marie F ^a   Mayer, Frank ^a   Molier, Michel ^a   Van Weeren, Pascale C ^a   Oosterhuis, J Wolter ^a   Bokemeyer, Carsten ^a   Looijenga, Leendert H J ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; DRUG EFFICACY; EMBRYONAL CARCINOMA; FEMALE; GERM CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTIS CANCER; WESTERN BLOTTING;

BLOTTING, WESTERN; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEMINOMA; TESTICULAR NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037087768     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.6.1551     Document Type: Article

References (68)

1. Do all germ cell tumor patients with residual masses in multiple sites require postchemotherapy resections?
2. A prognostic factor-based staging system for metastatic germ cell cancer's - International germ cell cancer collaborative group
3. Early stage and advanced seminoma: Role of radiation therapy, surgery, and chemotherapy
4. Testicular germ-cell cancer
5. Human testicular germ cell tumors show biallelic expression of the H 19 and IGF2 gene
6. Unique expression patterns of H 19 in human testicular cancers of different etiology
7. X inactivation in human testicular tumors: XIST expression and androgen receptor methylation status
8. Pathogenesis of testicular germ cell tumours
9. Germ cell neoplasms of the testis
10. The metastasis of human teratomas
11. Effects of multiple-drug chemotherapy (cis-diammine-dichloroplatinum, bleomycin, and vinblastine) on the maturation of retroperitoneal lymph node metastases of nonseminomatous germ cell tumors of the testis
12. Mechanisms of therapy-related differentiation in testicular germ cell tumours
13. Testis risk and prognostic factors: The pathologist's perspective
14. P53, bcl- 2 and bax immunoreactivity as predictors of response and outcome after chemotherapy for metastatic germ cell testicular tumours
15. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis
16. Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl-2 oncogene in primary testicular germ cell tumours
17. Drug resistance and sensitivity of germ cell testicular tumors: Evaluation of clinical relevance of MDRI/Pgp, p53, and metallothionein (MT) proteins
18. Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer?
19. Differential expression of p53, c-kit, and CD 34 in prepubertal and postpubertal testicular germ cell tumors
20. Germ cell tumors of the testis overexpress wild-type p 53
21. Molecular genetic changes in human male germ cell tumors
22. Prognostic significance of immunohistochemical proliferation markers (Ki-67/MIB-1 and proliferation-associated nuclear antigen), p53 protein accumulation, and neovascularization in clinical stage A nonseminomatous testicular germ cell tumors
23. The p53 and mdm-2 genes in human testicular germ-cell tumors
24. Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: Clinical correlation in stage I disease
25. The relationship of p53, PCNA, and S-phase in non-seminomatous germ cell tumors of the testis
26. The correlation of P53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis
27. p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia
28. The clinical relevance of p 53 expression in early stage nonseminomatous germ cell tumor
29. No germline TP 53 mutations detected in familial and bilateral testicular cancer
30. Primary mediastinal and testicular seminomas: A comparison of K-ras- 2 gene sequence and p53 immunoperoxidase analysis of 26 cases
31. Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters
32. The detection of p 53 gene mutation using a microdissection technique in primary intracranial germ cell tumors
33. Human male germ cell tumor resistance to cisplatin is linked to TP 53 gene mutation
34. Alterations of the p 53 tumor suppressor gene in carcinoma in situ of the testis
35. Increased p 53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors
36. Mutations of the p 53 gene are not detectable in human testicular tumors
37. Mutations of the p 53 gene do not occur in testis cancer
38. Identification of frequent p 53 gene alterations in testicular cancer by in situ molecular genetic and immunohistochemical analysis
39. p53 gene mutations in Chinese human testicular seminoma
40. Status of the p53 tumor suppressor gene and the MDM- 2 gene in human testicular tumors
41. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines
42. Regulation of p 53 stability by Mdm2
43. Mdm 2 promotes the rapid degradation of p53
44. Amplification and overexpression of the MDM 2 gene in a subset of human malignant gliomas without p53 mutations
45. p21/waf1/cip1 and mdm- 2 expression in breast carcinoma patients as related to prognosis
46. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities
47. Protein expression of MDM 2 and its clinicopathological relationships in human hepatocellular carcinoma
48. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma
49. mdm-2 expression in human testicular germ-cell tumors and its clinical value
50. Paraffin section storage and immunohistochemistry: Effects of time, temperature, fixation, and retrieval protocol with emphasis on p 53 protein and MIB 1 antigen
51. Cellular factors required for multiple stages of SV 40 DNA replication in vitro
52. Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts
53. Localization and polymorphism of a chromosome 12-specific alpha satellite DNA sequence
54. Alpha satellite DNA on chromosomes 10 and 12 are both members of the dimeric suprachromosomal subfamily, but display little identity at the nucleotide sequence level
55. Dual Alu polymerase chain reaction primers and conditions for isolation of human chromosome painting probes from hybrid cells
56. Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures
57. Identification of mutations leading to the Lesch-Nyhan syndrome by automated direct DNA sequencing of in vitro amplified cDNA
58. Polymorphism at codon 213 within the p53 gene
59. Increase in testicular cancer incidence in six European countries: A birth cohort phenomenon
60. p53 mutation and tamoxifen resistance in breast cancer
61. A functionally inactive p 53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation
62. Yolk-sac carcinoma develops spontaneously as a late occurrence in slow-growing teratoid tumors produced from transplanted 7-day mouse embryos
63. Cytogenetic analysis of murine embryo-derived tumors
64. Experimental testicular germ cell tumorigenesis in mouse strains with and without spontaneous tumours differs from development of germ cell tumours of the adult human testis
65. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines
66. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines
67. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer
68. Alternative and aberrant messenger RNA splicing of the mdm 2 oncogene in invasive breast cancer